Found: 10
Select item for more details and to access through your institution.
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
- Published in:
- 2012
- By:
- Publication type:
- journal article
131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-131-LB
- By:
- Publication type:
- Article
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial.
- Published in:
- European Journal of Heart Failure, 2021, v. 23, n. 9, p. 1529, doi. 10.1002/ejhf.2256
- By:
- Publication type:
- Article
Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure.
- Published in:
- European Journal of Heart Failure, 2020, v. 22, n. 12, p. 2393, doi. 10.1002/ejhf.2065
- By:
- Publication type:
- Article
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- Published in:
- 2019
- By:
- Publication type:
- journal article
Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
- Published in:
- European Heart Journal, 2021, v. 42, n. 13, p. 1203, doi. 10.1093/eurheartj/ehaa1007
- By:
- Publication type:
- Article
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
- Published in:
- European Heart Journal, 2021, v. 42, n. 6, p. 700, doi. 10.1093/eurheartj/ehaa943
- By:
- Publication type:
- Article
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
- Published in:
- European Heart Journal, 2021, v. 42, n. 6, p. 671, doi. 10.1093/eurheartj/ehaa968
- By:
- Publication type:
- Article